.jpg)
2024
Shanghai, Feb, 20, 2024, Haihe Biopharma Co., Ltd. (hereby referred to as “Haihe Biopharma” or the “Company”) today announced that two preclinical researches have been selected in Late-Breaking Research 2024 AACR（American Association for Cancer Research）Annual Meeting, which will be hold on Apr.5th to 10th, 2024 in San Diego, CA. As the focus of cancer research community, this meeting will invite scientists worldwide to share and discuss on latest scientific and medical research in this field.
Late-Breading Research is a key session in AACR annual meeting. This session will exhibit edge-cutting discoveries in tumor basic research and most advanced methods in tumor therapies. Two preclinical research of Haihe Biopharma have been selected in Late-Breaking Research, showing well-accepted innovation and clinical potential of company’s pipeline.
Title: Discovery and Characterization of HH100937, a potent and selective SOS1 inhibitor demonstrates synergistic efficacy in combination with KRAS/MAPK therapies
Session Title: Late-Breaking Research: Chemistry
Session Date and Time: Sunday Apr 7, 2024 1:30 PM - 5:00 PM
locations: Poster Section 52
Poster Board Number: 13
Abstract Presentation Number: LB031
Title: HH102007 is a highly selective and potent PARP1 inhibitor and trapper
Session Title: Late-Breaking Research: Chemistry
Session Date and Time: Sunday Apr 7, 2024 1:30 PM - 5:00 PM
locations: Poster Section 52
Poster Board Number: 14
Abstract Presentation Number: LB032
The American Association for Cancer Research (AACR) was founded in 1907. The AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. The AACR has more than 50,000 members residing in 129 countries and territories. Membership includes 256 Fellows of the AACR Academy and 54 Nobel laureates. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.
Haihe Biopharma Co., Ltd is a global, values-based, R&D driven biopharmaceutical leader headquartered in China with operation centers in the US and Japan, and mainly focuses on innovative anti-tumor therapies. The company has the fully capability of drug discovery, development, manufacturing and commercialization and delivers life-saving therapies to cancer patients in China, even the world widely. As a R&D focused company with many experts skilled in developing new drugs, Haihe Biopharma is committed in-house innovator with global perspective management and R&D team. Currently Haihe Biopharma has one approved product (Gumarontinib, Haiyitan®) in China and several drug candidates.
